Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 34.25% | -50.39% | 13.92% | -6.68% | -80.32% |
| Total Depreciation and Amortization | 290.91% | 0.00% | 46.67% | 0.00% | -31.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -116.38% | 752.88% | 1,626.51% | -99.01% | 444.65% |
| Change in Net Operating Assets | -375.06% | 362.10% | 47.84% | -124.11% | 151.02% |
| Cash from Operations | -73.81% | 22.40% | 21.81% | -185.55% | 37.87% |
| Capital Expenditure | -- | 100.00% | -93.33% | -114.29% | 90.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -163.95% | 653.61% | 210.69% | 87.92% | -- |
| Cash from Investing | -163.95% | 654.88% | 210.40% | 87.91% | -171,612.00% |
| Total Debt Issued | -- | -- | -- | -- | 14,100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 90.06% |
| Issuance of Common Stock | 19,537.10% | 1,281.25% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -970.03% |
| Cash from Financing | 23,380.80% | 1,284.62% | -- | -- | 70.50% |
| Foreign Exchange rate Adjustments | 845.71% | 615.91% | -97.87% | 118.09% | -197.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 145.43% | 515.23% | 63.86% | 59.30% | -390.21% |
